Amgen Reports Q2 2026 Earnings Beat With Raised Full-Year Outlook
Macro·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen reported its second quarter 2026 financial results, showcasing an earnings beat that exceeded analysts' expectations. The company also raised its full-year outlook while announcing the discontinuation of AMG 513.
The earnings report reflects Amgen's strong performance in the healthcare sector, contributing to a positive market reaction. The decision to drop AMG 513 indicates a strategic shift in the company's product pipeline.
Amgen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS”
SEC Filing — AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS“Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513”
Yahoo Finance — Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513